NYXH Earnings

NYXH reported its earnings on 2026-03-18, showcasing a revenue of against an estimate of 6.74M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.65 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following NYXH's earnings announcement on 2026-03-18, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, NYXH's stock price tends to shift by an average of 4.61% in the 10 days leading up to earnings and -1.14% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate NYXH's annual revenue to reach 3.47M, while the EPS is projected at -0.54. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between NYXH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, NYXH's stock price typically moves by 4.61% in the 10 days before its earnings and -1.14% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.54 and revenue of 3.47M.

The earnings call highlights significant positives such as FDA approval and strong U.S. market entry, with a trained sales force and growing physician interest. Despite increased operating losses and a slight gross margin decline due to U.S. investments, optimistic guidance and strategic plans for expansion and reimbursement suggest positive momentum. The Q&A reinforced positive sentiment, with excitement over the Genio system's unique offering. However, the lack of detailed revenue breakdowns and increased cash burn are concerns. Overall, the strategic U.S. launch and promising guidance outweigh the negatives, suggesting a likely positive stock movement.